Ultragenyx, Mereo crash on late-stage bone disease failure

The rare bone dis­ease drug be­ing de­vel­oped by Ul­tragenyx Phar­ma­ceu­ti­cal and Mereo Bio­Phar­ma has cat­e­gor­i­cal­ly failed in its late-stage pro­gram, the part­ners re­vealed Mon­day. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.